| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Jason P Rhodes is Director at REPL and has filed Form 4s across 3 companies. Jason P Rhodes's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $27.3M at current prices.
Historically, Jason P Rhodes's trades have earned a strong insider score of 77/100 across 45 rated trades. Over a 12-month horizon, 96.4% of those trades were profitable, with an average 12-month return of +58.2%.
The biggest single holding is REPL (~$19.5M) as Director. Net of sales, the REPL filings show accumulation of 704,046 shares.
Jason P Rhodes has 47 Form 4 filings on record from July 2018 to August 2026, across 4 companies: Director at Dyne Therapeutics (DYN), 2020–2026; Director at Generation Bio (GBIO), 2020–2025; Director at Replimune Group (REPL), 2018–2022, and 1 more.
The 252 reported transactions were 226 open-market sales, 18 option or other derivative awards, 5 conversions and 2 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $25.0M and 24 sales worth about $209.3M.
The largest open-market purchase was 1,100,000 shares of REPL at an average $13.61 on November 18, 2019, about $15.0M.
The largest open-market sale was 2,586,928 shares of DYN at an average $25.20 on August 14, 2026, about $65.2M.
12 of the 13 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | DYN Dyne Therapeutics, Inc. | Director | Sell10b5-1 | 2,586,928 | $25.20 | $65,184,894.40 | -85.8% | - | - | |
| Jul 7, 2026 | DYN Dyne Therapeutics, Inc. | Director | Sell10b5-1 | 777,451 | $22.97 | $17,858,491.67 | -99.6% | -35.2% | - | |
| Jun 29, 2026 | DYN Dyne Therapeutics, Inc. | Director | Sell10b5-1 | 504,695 | $21.23 | $10,712,549.82 | -34.1% | -23.1% | - | |
| Jun 25, 2026 | DYN Dyne Therapeutics, Inc. | Director | Sell10b5-1 | 267,760 | $21.09 | $5,646,496.80 | -19.9% | -21.3% | - | |
| May 6, 2026 | DYN Dyne Therapeutics, Inc. | Director | Sell10b5-1 | 106,723 | $18.14 | $1,936,341.42 | -8.6% | +37.8% | - | |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | Director | Sell10b5-1 | 274,398 | $18.38 | $5,043,484.22 | -97.0% | +41.1% | - | |
| Apr 27, 2026 | DYN Dyne Therapeutics, Inc. | Director | Sell10b5-1 | 384,549 | $18.47 | $7,101,119.51 | -24.2% | +42.1% | - | |
| Apr 22, 2026 | DYN Dyne Therapeutics, Inc. | Director | Sell10b5-1 | 834,302 | $19.75 | $16,477,387.75 | -39.4% | +21.1% | - | |
| Nov 14, 2024 | DYN Dyne Therapeutics, Inc. | Director | Sell | 782 | $33.10 | $25,884.20 | - | -54.1% | -38.0% | |
| Mar 1, 2024 | DYN Dyne Therapeutics, Inc. | Director | Sell10b5-1 | 46,534 | $30.05 | $1,398,346.70 | -5.2% | +7.1% | -53.3% |